STN-Structure Search 1/11/07

10/551,816

=> d ibib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:927208 CAPLUS
DOCUMENT NUMBER: 141:395550
TITLE: Processes for producing carboxyphenylindazole derivatives as intermediates for pyrazoloacridone derivatives
INVENTOR(S): Tsubakihara, Nobuaki; Katsuhira, Takeshi; Kinugawa, Masahiko; Kato, Nobuyuki
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2004094423 | A1 | 20041104 | WO 2004-JP5891 | | 20040423 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| AU 2004232605 | A1 | 20041104 | AU 2004-232605 | | 20040423 |
| EP 1627877 | A1 | 20060222 | EP 2004-729194 | | 20040423 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | | |
| US 2006217554 | A1 | 20060928 | US 2005-551816 | | 20050930 |
| PRIORITY APPLN. INFO.: | | | JP 2003-119943 | A | 20030424 |
| | | | WO 2004-JP5891 | W | 20040423 |

OTHER SOURCE(S): MARPAT 141:395550
GI




I

AB Carboxyphenylindazole derivs. I [R = alkyl; R1 = H, CH2X, etc.; R2 = H, nitro, etc.; X = H, OH, etc.], useful as intermediates for antitumor pyrazoloacridone derivs., are prepared, e.g. by reaction of indazole derivs. with fluoroalkoxybenzonitrile derivs., followed by hydrolysis of the resulting cyanophenylindazole derivs. Thus, reaction of 2-fluoro-6-methoxybenzonitrile with 3-methyl-6-nitroindazole in the presence of potassium carbonate in DMF, followed by hydrolysis of the

product, gave 1-(2-carboxy-3-methoxyphenyl)-3-methyl-6-nitroindazole.

IT 786658-34-2P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for producing carboxyphenylindazole derivs. as intermediates for pyrazoloacridone derivs.)

RN 786658-34-2 CAPLUS

CN Benzonitrile, 2-methoxy-6-(3-methyl-6-nitro-1H-indazol-1-yl)- (9CI) (CA INDEX NAME)




IT 786658-39-7P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for producing carboxyphenylindazole derivs. as intermediates for pyrazoloacridone derivs.)

RN 786658-39-7 CAPLUS

CN Benzonitrile, 2-fluoro-6-(3-methyl-6-nitro-1H-indazol-1-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d re 1-5

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
RE
(1) Kyowa Hakko Kogyo Co Ltd; JP 02-76878 A 1990 CAPLUS
(2) Kyowa Hakko Kogyo Co Ltd; EP 347749 A1 1990 CAPLUS
(3) Kyowa Hakko Kogyo Co Ltd; US 5079358 A 1990 CAPLUS
(4) Kyowa Hakko Kogyo Co Ltd; JP 06-107641 A 1994 CAPLUS
(5) Kyowa Hakko Kogyo Co Ltd; JP 07-48355 A 1995 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 10:20:25 ON 11 JAN 2007)

FILE 'REGISTRY' ENTERED AT 10:20:45 ON 11 JAN 2007
L1 STRUCTURE UPLOADED
L2 0 S L1

L3 2 S L1 FULL

FILE 'CAPLUS' ENTERED AT 10:21:21 ON 11 JAN 2007
L4 1 S L3

=> d l1
L1 HAS NO ANSWERS
L1 STR




G1

G1 MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO,X

Structure attributes must be viewed using STN Express query preparation.

=> => d ibib abs hitstr

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:927208 CAPLUS
DOCUMENT NUMBER: 141:395550
TITLE: Processes for producing carboxyphenylindazole derivatives as intermediates for pyrazoloacridone derivatives
INVENTOR(S): Tsubakihara, Nobuaki; Katsuhira, Takeshi; Kinugawa, Masahiko; Kato, Nobuyuki
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004094423 | A1 | 20041104 | WO 2004-JP5891 | 20040423 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004232605 | A1 | 20041104 | AU 2004-232605 | 20040423 |
| EP 1627877 | A1 | 20060222 | EP 2004-729194 | 20040423 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |

IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

| | | | | | |
|---|---|---|---|---|---|
| US 2006217554 | A1 | 20060928 | US 2005-551816 | | 20050930 |
| PRIORITY APPLN. INFO.: | | | JP 2003-119943 | A | 20030424 |
| | | | WO 2004-JP5891 | W | 20040423 |

OTHER SOURCE(S): MARPAT 141:395550
GI



I

AB Carboxyphenylindazole derivs. I [R = alkyl; R1 = H, CH2X, etc.; R2 = H, nitro, etc.; X = H, OH, etc.], useful as intermediates for antitumor pyrazoloacridone derivs., are prepared, e.g. by reaction of indazole derivs. with fluoroalkoxybenzonitrile derivs., followed by hydrolysis of the resulting cyanophenylindazole derivs. Thus, reaction of 2-fluoro-6-methoxybenzonitrile with 3-methyl-6-nitroindazole in the presence of potassium carbonate in DMF, followed by hydrolysis of the product, gave 1-(2-carboxy-3-methoxyphenyl)-3-methyl-6-nitroindazole.

IT 786658-34-2P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for producing carboxyphenylindazole derivs. as intermediates for pyrazoloacridone derivs.)

RN 786658-34-2 CAPLUS

CN Benzonitrile, 2-methoxy-6-(3-methyl-6-nitro-1H-indazol-1-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:20:25 ON 11 JAN 2007)

FILE 'REGISTRY' ENTERED AT 10:20:45 ON 11 JAN 2007

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 2 S L1 FULL

```
     FILE 'CAPLUS' ENTERED AT 10:21:21 ON 11 JAN 2007
L4             1 S L3

     FILE 'REGISTRY' ENTERED AT 10:22:52 ON 11 JAN 2007
L5               STRUCTURE UPLOADED
L6             0 S L5
L7             1 S L5 FULL

     FILE 'CAPLUS' ENTERED AT 10:23:58 ON 11 JAN 2007
L8             1 S L7

=> d l5
L5 HAS NO ANSWERS
L5                STR
```




```
G1 MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO,X


Structure attributes must be viewed using STN Express query preparation.


=>
```

=> d ibib abs hitstr 1-5

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:149503 CAPLUS
DOCUMENT NUMBER: 139:254492
TITLE: KW-2170 (Kyowa Hakko Kogyo)
AUTHOR(S): Verschraegen, Claire F.
CORPORATE SOURCE: UNM Cancer Research and Treatment Center, Albuquerque, NM, 87131, USA
SOURCE: IDrugs (2002), 5(10), 1000-1003
CODEN: IDRUFN; ISSN: 1369-7056
PUBLISHER: PharmaPress Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. The pyrazoloacridone KW-2170, an alkylating agent and topoisomerase II inhibitor, is being developed by Kyowa Hakko Kogyo as a potential treatment for cancer. By Dec. 2001, KW-2170 had entered phase II trials in the US, following approval for the trial from the FDA, which was received in Nov. 2001. At this time, the company planned to extend the phase II trials to Australia, Singapore, Taiwan and Costa Rica, using data from US phase I trials. Accelerated Japanese trials were also planned, and an NDA was anticipated for 2006, with non-small-cell lung cancer, prostate cancer, colorectal cancer, ovarian cancer and breast cancer as the targets. By August 2002, Japanese phase I trials had been completed.

IT 207862-44-0P, KW 2170
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(KW-2170 pharmacol. as antitumor agent)
RN 207862-44-0 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[(2-hydroxyethyl)amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:376708 CAPLUS
DOCUMENT NUMBER: 131:170298
TITLE: An efficient synthesis of a new class of DNA intercalating antitumor 7,10-dihydroxy-6H-pyrazolo[4,5,1-de]acridin-6-ones
AUTHOR(S): Mimura, Takashi; Kato, Nobuyuki; Sugaya, Toru; Ikuta,

Masanori; Kato, Sachiko; Kuge, Yukihiro; Tomioka, Shinji; Kasai, Masaji
CORPORATE SOURCE: Sakai Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Sakai, 590, Japan
SOURCE: Synthesis (1999), (6), 947-952
CODEN: SYNTBF; ISSN: 0039-7881
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 131:170298
AB An efficient synthesis of KW-2170, a 7,10-dihydroxy-6H-pyrazolo[4.5.1-de]acridin-6-one, is described. The selective monobromination of the Me group before the cyclization to the pyrazoloacridone is easily carried out. In the improved process, the bromination of the corresponding Me group is achieved prior to the hydroquinone formation, so the protection of the hydroxy groups is not necessary unlike the original method. In comparison with the original synthetic route of KW-2170, the new route decreases the synthetic steps from 2,6-Br(MeO)C6H3CO2H from 15 to 13 and increases the overall yield from 2 to 12%.

IT 238756-65-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of KW-2170, hydroxypyrazoloacridinone)

RN 238756-65-5 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-8-bromo-7,10-dihydroxy-2-[[(2-hydroxyethyl)(phenylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




IT 207862-44-0P, KW-2170
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of KW-2170, hydroxypyrazoloacridinone)

RN 207862-44-0 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[(2-hydroxyethyl)amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:909448 CAPLUS
DOCUMENT NUMBER: 123:313951
TITLE: Preparation of pyrazoloacridones as antitumor agents
INVENTOR(S): Kato, Nobuyuki; Mimura, Takashi; Ikuta, Masanori; Iida, Sachiko; Sugaya, Tooru; Kasai, Masaji; Tomioka, Shinji
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 07165758 | A | 19950627 | JP 1993-315123 | 19931215 |
| JP 3283369 | B2 | 20020520 | | |
| PRIORITY APPLN. INFO.: | | | JP 1993-315123 | 19931215 |

OTHER SOURCE(S): CASREACT 123:313951; MARPAT 123:313951
GI



I



II

AB Claimed is the process for the preparation of pyrazoloacridones I [X = H, halo; W, Y = H, halo, etc.] by reduction of pyrazoloacridinetriones II [X, W, Y = as defined above]. I are antitumor agents (no data). Thus, reduction of II [X = Y = Br; W = H] by sodium hydrosulfite gave I [X = Y = Br; W = H].

IT 142853-45-0P 170105-05-2P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazoloacridones as antitumor agents)

RN 142853-45-0 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[(2-hydroxyethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 170105-05-2 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 8-bromo-7,10-dihydroxy-2-[[(2-hydroxyethyl)(phenylmethyl)amino]methyl]-5-[(phenylmethyl)[3-[(phenylmethyl)amino]propyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:867580 CAPLUS
DOCUMENT NUMBER: 123:256702
TITLE: Preparation of acridone and pyrazoloacridinone derivatives as intermediates for antitumor agents
INVENTOR(S): Ikeda, Shunichi; Kasai, Masaji; Saito, Hiromitsu
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 PP.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 07048355 | A | 19950221 | JP 1993-192105 | 19930803 |
| PRIORITY APPLN. INFO.: | | | JP 1993-192105 | 19930803 |

OTHER SOURCE(S): MARPAT 123:256702
GI



I



II

AB The title compds. I [R1, R2 = alkyl; X = H, halo; Y1 = H; Y2 = O, etc.; or Y1Y2 = N; Z = H, halo, etc.] are claimed. Pyrazoloacridinone II was prepared in a multiple step process from 4-acetyl-1-bromo-5,8-dimethoxy-9(10H)-acridone.

IT 142853-41-6P 142853-45-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of acridone and pyrazoloacridinone derivs. as intermediates for antitumor agents)

RN 142853-41-6 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-2-[[(2-aminoethyl)amino]methyl]-7,10-dihydroxy- (9CI) (CA INDEX NAME)



RN 142853-45-0 CAPLUS

CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[(2-hydroxyethyl)amino]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:490167 CAPLUS

DOCUMENT NUMBER: 117:90167

TITLE: Pyrazoloacridone derivatives and pharmaceuticals with antitumor activity containing them

INVENTOR(S): Mimura, Yukiteru; Shida, Yasushi; Kasai, Masaji;

Ashizawa, Tadashi; Gomi, Katsushige
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 487097 | A1 | 19920527 | EP 1991-119896 | 19911121 |
| EP 487097 | B1 | 19981014 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| JP 05001064 | A | 19930108 | JP 1991-301727 | 19911118 |
| JP 06076409 | B | 19940928 | | |
| US 5220026 | A | 19930615 | US 1991-793522 | 19911118 |
| AT 172200 | T | 19981015 | AT 1991-119896 | 19911121 |
| ES 2125859 | T3 | 19990316 | ES 1991-119896 | 19911121 |

PRIORITY APPLN. INFO.: JP 1990-320438 A 19901122
OTHER SOURCE(S): CASREACT 117:90167; MARPAT 117:90167
GI




I

AB Certain pyrazoloacridone derivs. and pharmaceuticals with antitumor activity containing same are claimed. Treatment of 2-(bromomethyl)-5,8-dibromo-7,10-dimethoxypyrazolo[4,5,1-d,e]acridin-6-one with ethylenediamine followed by debromination and treatment with HBr to give 5-[(2-aminoethyl)amino]-2-[[(aminoethyl)amino]methyl]-7,10-dihydroxypyrazolo[4,5,1-d,e]acridin-6-one (I). I was active against P388 ascites tumor in mice.

IT 142853-41-6P 142853-42-7P 142853-43-8P
142853-44-9P 142853-45-0P 142853-46-1P
142853-47-2P 142853-48-3P 142853-49-4P
142853-50-7P 142853-51-8P 142853-52-9P
142853-53-0P 142853-54-1P 142853-57-4P
142853-61-0P 142853-64-3P 142853-67-6P
142853-70-1P 142853-73-4P 142853-76-7P
142853-79-0P 142853-83-6P 142853-87-0P
142853-89-2P 142853-92-7P 142853-95-0P
142853-98-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as neoplasm inhibitor)

RN 142853-41-6 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-2-[[(2-aminoethyl)amino]methyl]-7,10-dihydroxy- (9CI) (CA INDEX NAME)



RN 142853-42-7 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-2-[(diethylamino)methyl]-7,10-dihydroxy- (9CI) (CA INDEX NAME)



RN 142853-43-8 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 2-[(diethylamino)methyl]-5-[[2-(dimethylamino)ethyl]amino]-7,10-dihydroxy- (9CI) (CA INDEX NAME)



RN 142853-44-9 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-7,10-dihydroxy-2-[[(2-hydroxyethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 142853-45-0 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[(2-hydroxyethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 142853-46-1 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-5-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-2-[[(2-hydroxyethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 142853-47-2 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-2-[[(2-hydroxyethyl)amino]methyl]-5-[[2-(methylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 142853-48-3 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[[2-(dimethylamino)ethyl]amino]-7,10-dihydroxy-2-[[(2-hydroxyethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 142853-49-4 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 2-[[bis(2-hydroxyethyl)amino]ethyl]-5-[[2-(dimethylamino)ethyl]amino]-7,10-dihydroxy- (9CI) (CA INDEX NAME)



RN 142853-50-7 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-7,10-dihydroxy-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 142853-51-8 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-7,10-dihydroxy-2-[[(2-methoxyethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 142853-52-9 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-5-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 142853-53-0 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 142853-54-1 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]-5-[[2-(4-morpholinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 142853-57-4 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-2-[[(2-aminoethyl)amino]methyl]-7,10-dihydroxy-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 142853-61-0 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-2-[(diethylamino)methyl]-7,10-dihydroxy-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 142853-64-3 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 2-[(diethylamino)methyl]-5-[[2-(dimethylamino)ethyl]amino]-7,10-dihydroxy-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 142853-67-6 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-7,10-dihydroxy-2-[[(2-hydroxyethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142853-70-1 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-

dihydroxy-2-[[(2-hydroxyethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142853-73-4 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-5-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-2-[[(2-hydroxyethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142853-76-7 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-2-[[(2-hydroxyethyl)amino]methyl]-5-[[2-(methylamino)ethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142853-79-0 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[[2-(dimethylamino)ethyl]amino]-7,10-dihydroxy-2-[[(2-hydroxyethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142853-83-6 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 2-[[bis(2-hydroxyethyl)amino]methyl]-5-[[2-(dimethylamino)ethyl]amino]-7,10-dihydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142853-87-0 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-7,10-dihydroxy-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142853-89-2 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(2-aminoethyl)amino]-7,10-dihydroxy-2-[[(2-methoxyethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142853-92-7 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-5-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142853-95-0 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 142853-98-3 CAPLUS
CN 6H-Pyrazolo[4,5,1-de]acridin-6-one, 7,10-dihydroxy-2-[[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]methyl]-5-[[2-(4-morpholinyl)ethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

```
=> d his

     (FILE 'HOME' ENTERED AT 10:33:53 ON 11 JAN 2007)

     FILE 'REGISTRY' ENTERED AT 10:34:07 ON 11 JAN 2007
L1             STRUCTURE UPLOADED
L2               4 S L1
L3              33 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 10:34:39 ON 11 JAN 2007
L4               5 S L3/PREP

=> d l1
L1 HAS NO ANSWERS
L1                STR
```



Structure attributes must be viewed using STN Express query preparation.

=>